Our SGK1 development pipeline
Precision medicine through serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibition, across electrical and structural heart disease and beyond.
Program details
-
Wave II: Phase 2/3 trial enrolling people aged 15 and older with LQTS Type 2 in the United States
LQTS Type 3 enrollment in Wave II is anticipated in 2027
FDA Fast Track Designation
-
Targeting residual risk from pathological electrical and structural remodeling despite guideline-directed medical therapy
Human genetic validation of SGK1 in heart failure, plus preclinical data showing superior efficacy versus a leading SGLT2 inhibitor Read the paper
Phase 1 data showing robust, clinically meaningful QTc reduction in obese participants Read the paper
Phase 2a ASPIRE-HF in HFrEF with QTc prolongation, enrolling soon
FDA IND clearance for heart failure
-
Targeting pathological remodeling in AF to reduce arrhythmia burden and recurrence
Atrial SGK1 is upregulated in people with AF and obesity
Robust preclinical proof-of-concept data
-
SGK1 activation is implicated in the structural and electrical remodeling that drives cardiomyopathies
SGK1-driven structural and electrical remodeling converge across heart failure and cardiomyopathy populations
-
Multiple active discovery and preclinical programs across other cardiovascular diseases, CNS diseases and additional non-CNS indications where SGK1 activation drives disease biology.
The safety and efficacy of THRV-1268 have not been established. THRV-1268 is investigational; these research programs do not establish a treatment benefit. THRV-1268 has not been approved for commercial use by any regulatory authority (e.g., the FDA in the United States, Health Canada in Canada, or the TGA in Australia).